title: The impact of H. pyiori eradication on response to oral iron therapy in patients with iron deficiency anemia.
abstract: Infection with Helicobacter pylori has been associated with Iron deficiency anemia (IDA). We assessed the effect of eradication of H. pylori infection on response to oral iron treatment. Twenty patients with IDA of no obvious cause, unresponsive to oral iron therapy with positive gastric biopsy for H. pyJoril infection received sequential eradication therapy for 10 days followed by oral iron therapy. Treated patients were followed up at 6 weeks and 12 weeks post eradication to assess dynamic changes in hemoglobin, serum ferritin and transferrin saturation. While 65% of anemic H. pylori infected cases had pangpstritis, 35% had antral gastritis. In the antrum severe and moderate gastritis were found in 40% and 45% of cases, respectively. Hemoglobin and serum ferritin level correlated inversely with grade of gastritis (P <0.001). Improvement in hematological parameters and serum iron profile was observed 6 weeks and 12 weeks post successful H. eradication oral iron therapy. In conclusion, eradication of H. pylori infection enhances the response to oral iron supplementation in patients with refractory IDA. Screening and eradication of H. pylori should be a standard procedure for patients with IDA.
authors.affiliation: Departments of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
authors.forename: Nesreen A
authors.initials: NA
authors.lastname: Kotb
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Bedewy
authors.forename: Hanan H
authors.initials: HH
authors.lastname: Soliman
authors.forename: Hala M
authors.initials: HM
authors.lastname: Nagy
authors.forename: Eman A
authors.initials: EA
authors.lastname: Hasby
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D013270:Stomach / Q000382:microbiology / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D007501:Iron